Detalhe da pesquisa
1.
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Br J Clin Pharmacol
; 89(7): 2190-2200, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740580
2.
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Pediatr Infect Dis J
; 41(3): 230-237, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34817414
3.
In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
J Clin Pharmacol
; 48(10): 1179-88, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18676693
4.
The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.
Br J Clin Pharmacol
; 66(2): 233-9, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18429968
5.
Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
J Clin Pharmacol
; 46(5): 577-87, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16638741
6.
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.
J Clin Pharmacol
; 55(9): 1042-50, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25857714
7.
Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.
Adv Drug Deliv Rev
; 56(12): 1825-57, 2004 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-15381336
8.
Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Clin Pharmacol Drug Dev
; 3(5): 338-45, 2014 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27129005
9.
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.
J Pharm Sci
; 100(10): 4074-89, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21452299
10.
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
J Pharm Sci
; 100(10): 4111-26, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21480234
11.
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
J Pharm Sci
; 100(10): 4050-73, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21523782
12.
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
J Pharm Sci
; 100(10): 4127-57, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21541937
13.
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
J Pharm Sci
; 100(10): 4090-110, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21541938
14.
Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
J Pharm Sci
; 99(2): 1046-62, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19569219
15.
Monitoring liver safety in drug development: the GSK experience.
Regul Toxicol Pharmacol
; 49(2): 90-100, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17655994
16.
Synthesis and evaluation of potent and selective beta3 adrenergic receptor agonists containing heterobiaryl carboxylic acids.
Bioorg Med Chem Lett
; 17(16): 4670-7, 2007 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17560786
17.
The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.
Br J Clin Pharmacol
; 62(3): 336-44, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16934050
18.
Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
Antimicrob Agents Chemother
; 49(7): 2802-6, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15980352
19.
Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.
Pharmacology
; 72(2): 92-8, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15331914
20.
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
J Pharmacol Exp Ther
; 303(3): 1029-37, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12438524